Latest End point of clinical trials Stories
Aldoxorubicin Demonstrates 2-Fold Increase in Likelihood of Surviving More than 2 Years versus Doxorubicin and 27% Reduction in the Risk of Death LOS ANGELES, Jan.
Continued Positive Trends in Overall Survival and Progression-Free Survival; LOS ANGELES, Nov. 14, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd.
SUNNYVALE, Calif., Oct. 17, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
AUSTIN, Texas, Sept.
New research suggests that how quickly mesothelioma progresses after treatment may predict the likelihood of survival better than treatment response. Raleigh,
Important New Variable Covered. Threshold for Meeting Primary Endpoint Lowered. BETHESDA, Md., Aug.
Latest Data Sweep from a 285 Patient Subgroup Shows An Impressive 57% Improvement in Overall Survival LAWRENCEVILLE, N.J., July 28, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ:
SUNNYVALE, Calif., July 25, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
Despite strong preclinical data, the drug everolimus failed to improve overall survival in patients with advanced liver cancer, compared to placebo.
In patients with advanced uveal melanoma, treatment with the agent selumetinib, compared with chemotherapy, resulted in an improved cancer progression-free survival time and tumor response rate, but no improvement in overall survival.